Xaira’s War on Trial-and-Error Drug Development

The integration of artificial intelligence into the drug discovery process aims to reduce development timelines and improve success rates by shifting from artisanal, trial-and-error methods to data-driven, *in silico* modeling. Xaira, led by CEO Marc Tessier-Lavigne, focuses on three critical stages: target identification, drug design, and patient stratification. Generative AI allows for the creation of therapeutics against previously "undruggable" targets, such as complex membrane proteins, by utilizing massive causal datasets rather than relying on descriptive data. The pharmaceutical industry currently faces Eroom’s Law, where development costs double every few years; AI offers a potential reversal of this trend by increasing clinical success rates from 10% to 30-40% and halving the standard 13-year development cycle. While large pharmaceutical companies hold significant historical data, future breakthroughs depend on generating high-quality, prospective causal data in tightly controlled clinical environments.